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Outcome Prediction to Erlotinib in
Gastroesophageal Adenocarcinomas:
Can We Improve Epidermal
Growth Factor Receptor and
Phospho-AKT Testing?
TO THE EDITOR: I read with great interest the recently published
study by Dragovich et al,1 who reported on molecular biomarkers
in a phase II trial of erlotinib for treatment of advanced gastro-
esophageal (GE) adenocarcinomas. Within a panel of candidate
predictive markers of response, they analyzed epidermal growth
factor receptor (EGFR) and phospho-AKT (pAKT) protein ex-
pression by immunohistochemistry (IHC) and EGFR gene status
by fluorescence in situ hybridization (FISH). EGFR and pAKT
expression were positive in 86% and 68% of tumor biopsies, re-
spectively. Responses to erlotinib were observed in 9% of patients
with gastroesophageal junction (GEJ) adenocarcinoma, and in 0%
of gastric cancer patients. Given such modest response rates, and
overall high frequency of EGFR- and pAKT-positive tumors, the
authors concluded that assessment of these two biomarkers does
not help to predict response. Furthermore, no EGFR amplification
by FISH analysis was detected in samples from patients responding
to erlotinib, and thus FISH does not appear to provide an adequate
tool to predict response either. In an attempt to interpret the lack of
predictive value yielded by IHC and FISH, this study actually does
raise a few points concerning relevant methodologic details that
warrant further discussion.
In the Methods section of their report, the authors state that
the slides were read as positive or negative for EGFR and pAKT
expression, and that positive stainingwas classified asweak (1) or
strong (2). However, they do not mention the percentage of
positive tumor cells they considered as the cutoff point to define
EGFR and pAKT positivity, nor do theymention the breakdown of
tumors deemed as 1 or 2 in terms of staining intensity. Never-
theless, the score they adopted implies that a positive result is
defined by any staining intensity (from 1 to 2) in a fraction of
tumor cells above a certain cutoff. Whether differences in scoring
criteria would also translate into differences of outcome prediction
is unknown. To define the level of expression of EGFR and pAKT
by IHC, other researchers2 reported a combined score based on the
percentage of positive tumor cells multiplied by the staining inten-
sity. Importantly, this score significantly correlated to clinical out-
come after gefitinib therapy in non–small-cell lung cancer
(NSCLC).2 Although caution remains mandatory in extrapolating
data from the non–small-cell lung cancer experience to GE can-
cers, it might be the case that a combined score expands the scope
of IHC to detect any differential EGFRor pAKT expression level on
a continuous scale. Whereas a positive result in the study by Cap-
puzzo et al2 might truly represent a high level of protein expression
being detected, in most of the reported studies, including the one
by Dragovich et al,1 a positive IHC result corresponds to any level
of protein expression being detected. Therefore, even if they may
have classified the staining intensities into two subcategories, weak
or strong, these differences in scoring criteria might explain why
their score failed to detect any correlation between protein expres-
sion and outcome.
From a technical point of view, some pitfalls might specifically
complicate the assessment of pAKT by IHC. Janmaat et al3 recently
found it particularly difficult to interpret pAKT staining in GEJ ade-
nocarcinomas because the surrounding healthy tissues do express
pAKT to some extent. Indeed, these investigators were able to assess
pAKT status in only eight GEJ samples with tumor-specific staining.3
As a result, they do not even recommend an evaluation of pAKT as a
predictor of response, although in their series some correlations could
be established between the staining incidence and the staining inten-
sity of this biomarker, and clinical outcome after gefitinib therapy.3
One can argue whether similar difficultiesmight also have intervened
in the study by Dragovich et al,1 thus further explaining why assess-
mentofpAKTdidnot retainany strongpredictive value in their study.
With regards to FISH analysis, the authors need to clarify how
they scored EGFR gene status and how they came up with the defini-
tion ofEGFR amplification. This is standard practice inmost publica-
tions. Although increased EGFR gene copy number inGE cancers has
been described in earlier investigations,4,5 the increased EGFR copy
number itself would probably be too low to define it as a marker for
gene amplificationbyFISHanalysis.Nevertheless, similar to the expe-
rience with gefitinib2,6 or erlotinib7 in NSCLC, if we exclude EGFR
amplification, there remains the possibility that other genetic aberra-
tions, for instance chromosome7polysomy,wouldhave tobe consid-
ered because of their possible impact on outcome prediction to
tyrosine kinase inhibitors.
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